{
    "root": "72b2e981-03dd-465e-ad71-75395a2cc624",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "LUTRATE DEPOT",
    "value": "20250314",
    "ingredients": [],
    "indications": "lutrate depot 22.5 mg 3-month ( leuprolide acetate ) indicated treatment advanced prostate cancer .",
    "contraindications": "due different release characteristics , strengths additive must selected based upon desired dosing schedule ( 2 ) . lutrate depot 22.5 mg 3 months , given single intramuscular injection every 12 weeks . ( 2.1 )",
    "warningsAndPrecautions": "lutrate\u00ae depot supplied kit consisting leuprolide acetate mixject single-dose delivery system consisting vial flip-off seal containing sterile , white white lyophilized leuprolide acetate microspheres incorporated biodegradable polymer , mixject vial adapter containing needle , pre-filled syringe containing clear sterile mannitol solution injection , usp , 2 ml , ph 4.5 7.0. lutrate\u00ae depot ( leuprolide acetate depot suspension ) 22.5 mg \u2013 ndc 83831-134-01 storage store controlled room temperature 20\u00b0-25\u00b0c ( 68\u00b0-77\u00b0f ) ; excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "lutrate depot contraindicated : hypersensitivity lutrate depot contraindicated individuals known hypersensitivity gnrh agonists excipients lutrate depot . reports anaphylactic gnrh agonists reported medical literature .",
    "indications_original": "LUTRATE DEPOT 22.5 mg for 3-month administration (leuprolide acetate) is indicated for treatment of advanced prostate cancer.",
    "contraindications_original": "Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule ( 2 ). LUTRATE DEPOT\u00a022.5 mg for 3 months administration, given as a single intramuscular injection every 12 weeks.\u00a0( 2.1 )",
    "warningsAndPrecautions_original": "LUTRATE\u00ae DEPOT\u00a0is supplied as a kit consisting of a\u00a0LEUPROLIDE ACETATE MIXJECT single-dose delivery system consisting of a vial with a Flip-Off seal containing sterile, white to off white lyophilized leuprolide acetate microspheres incorporated in a biodegradable polymer, a MIXJECT vial adapter containing the needle, and a pre-filled syringe containing clear sterile mannitol solution for injection, USP, 2 mL, pH 4.5 to 7.0.\n                  LUTRATE\u00ae DEPOT (leuprolide acetate for depot suspension)\u00a022.5 mg \u2013 NDC 83831-134-01\n                  \n                     Storage\n                  \n                  Store at controlled room temperature at 20\u00b0-25\u00b0C (68\u00b0-77\u00b0F); excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "LUTRATE DEPOT is contraindicated in:\n                  \n                  \n                     \n                        Hypersensitivity\n                         LUTRATE DEPOT is contraindicated in individuals with known hypersensitivity to GnRH agonists or any of the excipients in LUTRATE DEPOT. Reports of anaphylactic reactions to GnRH agonists have been reported in the medical literature."
}